Objective: Drug-coated balloons (DCBs) may increase durability of endovascular treatment of superficial femoral artery (SFA) disease while avoiding stent-related risks. The purpose of this study was to use meta-analytic data of DCB studies to compare the cost-effectiveness of potential SFA treatments: DCB, drug-eluting stent (DES), plain old balloon angioplasty (POBA), or bare-metal stent (BMS).
Peripheral arterial disease (PAD) affects one in five Americans by the age of 80 years according to recent epidemiologic data. 1 Because of increased awareness
and an aging population, the incidence of PAD continues to increase worldwide. 2, 3 The negative consequences of PAD on quality and length of life have been well reported, 4 but the economic burden of this disease is often underestimated. 3 The annual cost of treating PAD in the United States has been estimated to range from $212 billion to $389 billion, more than diabetes, coronary disease, or cancer. [5] [6] [7] Much of this cost is billed to publicly funded insurance. In 2012, 71% of hospital discharges for PAD were billed to Medicare (Healthcare Cost and Utilization Project query; International Classification of Diseases, Ninth Revision diagnosis codes 440. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] 443 .9, and 443.81). Moreover, an estimated 7% of all Medicare patients received treatment for PAD in a single year (2001) , which represents a significant payer burden. 3, 8 Thus, it is imperative that health care providers have objective evidence to make cost-effective decisions with regard to treatment of PAD. Advances in available percutaneous technology along with the associated lower morbidity and mortality (compared with bypass surgery) of endovascular therapy have made endovascular-first management of femoralpopliteal disease increasingly attractive and widespread. 9 Moreover, there is evidence that endovascular therapy first may be cost-effective, although long-term data are lacking. 10, 11 Emerging therapies of significance include drug-coated balloons (DCBs) and drug-eluting stents (DESs), which have the potential to improve patency rates of percutaneous interventions on the basis of the initial trials. 12 DCBs may specifically offer improved patency rates without stent-associated risks, such as fracture or in-stent restenosis. However, there is a scarcity of cost-effectiveness evidence to support this decisionmaking process. The goal of our study was twofold. First, we sought to perform a meta-analysis of the growing body of highquality literature for drug-coated therapies. We then applied these pooled data to a decision model to compare the cost-effectiveness of different index endovascular treatment modalities for superficial femoral artery (SFA) disease using a clinically relevant effectiveness outcome of patency rates. We hypothesized that drug-coated therapies would be costeffective from a payer perspective on a per-patient basis.
METHODS
Methods overview. This study was conducted with approval of the Institutional Review Board of the University of Pittsburgh. We conducted a systematic literature search for randomized clinical trials reporting primary patency (PP) or target lesion revascularization (TLR) for DES or DCB compared with any alternative therapy in the SFA or popliteal artery. Meta-analysis was performed first. Second, results from these studies were pooled and aggregated with additional literature-based parameter estimates to create a decision model to simulate cost-effectiveness of index therapy options (plain old balloon angioplasty [POBA], bare-metal stent [BMS], DCB, or DES) for SFA-popliteal disease. Effectiveness was defined as patency for our model. Other important definitions are summarized in Table I .
Literature search. To summarize the current evidence on DES and DCB, PubMed and Embase were systematically searched in December 2016 for all Englishlanguage, randomized clinical trials that compared DES or DCB with another mode of endovascular therapy for the SFA or popliteal artery. Studies were included if they reported either PP or TLR results at any time point. To focus on the highest quality data, studies were excluded if they were retrospective or observational or focused on treatment of restenotic lesions after a primary endovascular intervention. Single-arm studies were excluded.
Meta-analysis. Time-to-event outcomes, such as TLR, are most appropriately analyzed using hazard ratios, which account for the number and timing of events as well as censoring of patients lost to follow-up. 13 Odds ratios (ORs) or relative risks can be compared only when results are reported at specific time points for multiple studies (ie, 6 months or 1 year) and should not be combined for variable follow-up times. 13 Using ORs for meta-analysis excludes much of the available data on drug-eluting interventions because trials to date have variable lengths of follow-up reported. To maximize the available data, TLR hazard ratios were carefully extracted by recreating published Kaplan-Meier curves using the methodology described by Tierney et al. 13 The number of events and number of patients censored at each time point were estimated from the reported Kaplan-Meier curves and number at risk. When Kaplan-Meier curves were unavailable, ORs were calculated. This was done for the secondary outcomes of PP, major amputation, and death for DCBs at 1 year. Whereas two DES trials met our inclusion criteria, meta-analysis could not be performed on DES trials because of the lack of a consistent comparator between the two trials (ie, BMS or balloon angioplasty). Meta-analysis was performed using Stata 14 (StataCorp LP, College Station, Tex). The random-effects model was used to perform meta-analysis, allowing that the true effect size might differ from study to study on the basis of the characteristics of the patient and lesion.
Decision analytic model. A state transition decision analysis model was used as the primary method to simulate, by index procedure strategy, patency and associated costs. Index procedure options were POBA with bailout stenting, primary BMS, DES, and DCB (with bailout stenting). Several important assumptions were made in our model. First, open surgery (such as bypass surgery) was not an option because the available randomized controlled studies for drug-eluting therapies, from which our clinical parameters are derived, focused on short lesions and primarily Rutherford class 2 and 3 disease, for which a bypass is less likely to be chosen as the primary intervention.
14 In addition, atherectomy was not an index therapy option because of a lack of solid evidence to support its use as a primary treatment strategy in SFA disease. 15 No patients suffered limb loss in the model. Amputations are already known to be extremely costly, there is no evidence that these strategies differ with respect to amputation rates, and amputation was expected to be rare during the short follow-up time of the model. Clinical parameter assumptions. Clinical parameters were obtained from pooled weighted results from the aforementioned DES and DCB trials and additional literature search with the limited use of expert opinion to estimate parameters where published data were lacking. Major clinical parameters and primary references are summarized in Table II .
Cost assumptions. Costs were defined as reimbursements per procedure. Because the majority of PAD health care costs are billed to Medicare, we used a third-party payer perspective based on the current Centers for Medicare and Medicaid Services (CMS) outpatient hospital reimbursement rates. This perspective focuses on the efficiency of reimbursement for new technologies for a third-party payer and outcome that can have an impact on reimbursement policy.
The 2016 national CMS outpatient claims reimbursement averages for femoral-popliteal vascular territory treatment with POBA and BMS were obtained. Effective . 35 Because this payment varies on a case-by-case basis for each hospital, this TPT payment was estimated by first obtaining an average of our institutional Medicare claims reimbursement rates for DCB outpatient procedures. This institutional average was then adjusted to the national rate. Finally, the national average POBA reimbursement rate was subtracted to obtain the average TPT payment. Conversely, CMS determined in 2013 that Zilver PTX (Cook Medical, Bloomington, Ind) fit an existing passthrough category (C-code C1874) for outpatient procedures for which pass-through payment has expired. 36 Costs for DES were thus estimated by obtaining institutional Medicare claims reimbursement rates for femoral-popliteal stents with additional C-code C1874 and adjusting this to the national average. In light of the short time horizon, no discounting was applied. Cost inputs in the model are summarized in Table III .
Assessment of cost-effectiveness and sensitivity analysis. Effectiveness was defined as patency at the end of the time period. In the base model, the primary outcome was PP (ie, no reinterventions were performed). In the 2-year model, the primary outcome was overall patency (primary, primary assisted, and secondary patency). There is a lack of evidence linking patency and quality of life outcomes; thus, we did not correlate patency with quality-adjusted life-years. 37 The incremental cost-effectiveness ratio (ICER) was defined as the difference in payer costs divided by the difference in patencies at the end of the time period between two strategies. If an intervention generated higher patency rates at less payer cost than another intervention, the former dominated the latter. The number needed to treat (NNT) is the average number of patients who need to be treated to prevent one additional poor outcome (ie, loss of patency).
To explore the sensitivity of the model results to variations in parameter values, assumptions, and true effects of interventions, a range of univariable sensitivity analyses were performed. In addition, we relaxed assumptions, allowing the use of up to three devices (which significantly affects TPT reimbursement for DCB).
Further structural sensitivity analysis was performed by carrying the model out to 2 years, allowing up to one reintervention based on pooled TLR rates from the literature (Table II) . Again, the primary outcome in this model was overall patency, which included primary, primary assisted, and secondary patency. The methods of revascularization in the 2-year model are summarized in Table IV by index procedure. These proportions are based on literature values as well as expert opinion. 38 Because of a lack of published data, we assumed that a reintervention modality had the same patency rate as when it is used as the index procedure. Finally, we performed probabilistic sensitivity analysis on the 2-year model in which multiple parameters were randomly varied simultaneously over predefined probability distributions for 1000 iterations of the model. Clinical probabilities were approximated by beta distributions, and costs were approximated by gamma distributions. The models were developed and analyzed in TreeAge Pro 2015, R1.0 (TreeAge Software, Williamstown, Mass).
RESULTS
Systematic literature search. Seven DCB randomized studies met inclusion criteria for meta-analysis. The total number of subjects in all studies was 1248. Mean age ranged from 65.8 to 75.0 years per study; 61.5% to 69.2% of subjects were male. Included studies are summarized in Table V . DES trials are summarized in Table VI , although no meta-analysis was performed for these trials. Note should be made that mean lesion length treated ranged from 43.0 to 95.0 mm. In all studies, <20% of patients had critical limb ischemia, and the majority of patients in each study had nonocclusive disease.
Meta-analysis of DCB studies. By using hazard ratios extracted from reported Kaplan-Meier curves, we were able to perform meta-analysis of data from all seven randomized trials of DCBs (Fig 1) . DCB outperformed POBA with respect to TLR over time (pooled hazard ratio, 0.39; P < .001). Four studies reported PP at 1 year (Fig 2) . Meta-analysis showed significantly improved 1-year PP in the DCB group (pooled OR, 3.09; P ¼ .001). Risk of major amputation or death at 12 months was not significantly different between groups (P ¼ .80 and P ¼ .92, respectively).
Cost-effectiveness analysis. The initial decision for the decision analysis model is illustrated in Fig 3. In the original model, each scenario was carried out for 1 year. At the end of 1 year, the highest PP was seen in the DES index therapy strategy (79%), followed by DCB (74%), BMS (71%), and finally POBA (64%).
Cost-effectiveness results are summarized in Table VII Sensitivity analysis. Sensitivity analysis was used to vary selected parameters across a range of values to estimate the impact on cost-effectiveness analysis (Table VIII) . PP values were varied across the range of reported values to test the robustness of our results. Results held up across a variety of scenarios. If PP of DCBs was 79% or greater, both BMS and DES would be dominated by a DCB-first strategy. However, if PP for POBA at 1 year was >80%, it would become the dominant strategy. At current Medicare reimbursement rates, the use of two or more DCBs per procedure would no longer be cost-effective compared with BMS or DES. The 1-year time scenario without factoring in reintervention provides a comparison between strategies that requires the least number of assumptions or parameters based on expert opinion. However, to perform a more thorough and realistic analysis, we carried the model out to 2 years with the ability to perform at least one endovascular reintervention for a subset of patients who lost PP on the basis of pooled TLR data from major randomized trials. The primary outcome was patency at 2 years, which includes primary, primary assisted, and secondary patency. At 2 years, DCB was the dominant strategy with the highest patency and lowest cost of any strategy. Results of the 2-year scenario are summarized in Table IX . Univariate sensitivity analysis demonstrated that reintervention rates were the primary driver of cost-effectiveness at 2 years. Overall patency rates are similar between DCB (89%), DES (87%), and BMS (83%); however, because of the cost of reinterventions, DCB emerged as the dominant strategy.
Probabilistic sensitivity analysis was performed on the 2-year model, in which parameter values were simultaneously varied over distributions 1000 times. This showed that that DCB remained cost-effective over a range of parameter variations and willingness-to-pay thresholds (Fig 4) , although at very low thresholds (<$20,000), POBA is more likely to be a cost-effective option.
DISCUSSION
The TransAtlantic Inter-Society Consensus II document states that endovascular treatment of infrainguinal disease is the preferred treatment for stenosis or occlusion up to 10 cm in length.
14 It has been almost a decade since that document was published. In that time, many institutions and interventionalists have adopted an endovascular-first approach to the majority of femoropopliteal disease. 41 Although balloon angioplasty with bailout stenting has long been considered the standard of practice, a number of emerging therapies may improve the patency rates and consequently lower the TLR rates for endovascular treatment of SFA-popliteal disease. DCBs and DESs are two therapies that have emerged in recent years with randomized controlled trial evidence showing superior patency and decreased need for reintervention. The 5-year data for these technologies show possible long-term sustained benefits. In our model, we found DES and DCB to be associated with improved PP at 1 year and overall patency at 2 years compared with POBA or BMS. DES-first strategy has the highest 1-year PP (79%), followed by DCB-first (74%). Compared with the standard treatment of primary POBA with bailout stenting, the NNT for DCB was only 10.
Whereas slightly higher patency rates could be achieved with DES, the NNT compared with DCB was 20. Three of the four strategies, DCB, BMS, and DES, have comparable PP rates in the 70% to 80% range. Thus, the ICER between the DCB and stenting strategies is largely driven by cost differences rather than by patency differences. Even without considering reintervention costs, the drug-eluting treatment strategies seemed to come at a reasonable payer cost of $14,136.10 per additional patent limb for DCB and $38,549.80 per additional patent limb for DES. These represent "up-front" costs, which have potential to be offset by decreased reinterventions.
To test the robustness of this model to account for differences in outcomes due to variations in characteristics of the patient and lesion, we varied multiple parameters and evaluated the effect of those changes on costeffectiveness outcomes. We found that outcomes did not change dramatically over multiple expanded analyses. Notably, if PP rates of DCBs could exceed 79%, DCB would be the dominant strategy over BMS or DES by being the most effective and least costly option. Because of current adjusted Medicare reimbursements for DCBs, the use of more than one DCB per case decreases their cost-effectiveness dramatically from a payer perspective.
In the extended 2-year model, accounting for reinterventions, DCB emerged as the dominant strategy with superior patency and lowest payer cost at 2 years. This is despite the fact that assumed reinterventions after DCB included a high proportion of DES and BMS (the most expensive reinterventions from the payer perspective), adding validity to this conclusion.
Since the introduction of DESs and DCBs for treatment of infrainguinal PAD, initial results have been promising from both industry-sponsored trials and real-world data. Despite the increased cost of these devices, the improved PP rates have the potential to decrease longterm costs, which are known to be driven by the need for repeated interventions. 42 Real-world data are lacking, but several models across multiple national health care systems have shown this to be a valid assumption, including the one presented here. Decision analytic models have been performed in the German health care market, National Health Service in the United Kingdom, and Italian National Health Service. [42] [43] [44] In all analyses, drug-eluting therapies have been associated with cost savings to the health care system in question, with DCBs generally being found most cost-effective. This analysis represents one of the few costeffectiveness analyses of drug-eluting therapies from a U.S. payer perspective and the first model since the approval of these devices in the United States. The strengths of this study include the incorporation of more long-term data from the drug-eluting device trials rather than assumed constant hazard ratios. In addition, we have chosen to focus on the outcome of patency (vs quality-adjusted life-years) to compare costeffectiveness of various strategies, which eliminates much subjectivity associated with that measure. Notwithstanding, the results of our analysis are consistent with previously published results from health care systems around the world.
Limitations. There are several limitations to this analysis. First, the model is limited in time horizon because of a scarcity of published data with outcomes beyond 2 years.
In addition, as in all cost-effectiveness models, certain assumptions are made that may not be applicable in a real-world scenario. All attempts were made to use as few expert opinion parameters as possible and to base most inputs into the model on published data. For instance, because of a lack of data, we did not incorporate surgical bypass or amputations in our model. Most patients who have been included in drug-eluting trials to date have mostly had short-segment disease and generally included Rutherford class 2 or 3 disease, putting them at low risk of requiring open surgery or amputation in the 2-year time horizon. Thus, these results may not be valid for more complex disease. Moreover, published data are not available to account for the effect of index intervention on the patency of secondary interventions, although this effect is likely to be present. Finally, the majority of published, comparative data on drugeluting interventions comes from industry-sponsored pivotal trials, which are prone to publication bias. More real-world data collected during a longer time horizon are needed to account for multiple interventions and a broader spectrum of patients including those with critical limb ischemia.
In addition, we chose to use patency as our effectiveness outcome rather than quality of life or TLR because of its superior objectivity. According to the Society for Vascular Surgery reporting guidelines, TLR should not be considered an accurate primary outcome measure of efficacy after endovascular therapy. 45 In addition, quality of life data are lacking for drug-eluting therapies. Thus, we chose to compare therapies by patency rates. However, the willingness-to-pay threshold is undefined for patency rates, making true cost-effectiveness conclusions problematic unless one strategy is dominant. Finally, we chose to focus on cost as defined from the payer perspective. This is one of a number of valid perspectives from which to evaluate cost but an important one, given the established burden on publicly funded insurance. These data support the reimbursement, including adjusted pass-through payments, for drugeluting balloons. Certainly, a hospital-based cost perspective may yield somewhat different conclusions. However, local hospital negotiations can vary considerably and would be somewhat difficult to capture accurately.
CONCLUSIONS
Current data and Medicare reimbursements support the use of DCBs as a cost-effective strategy for endovascular intervention in the SFA. At 1 year, any additional effectiveness of DES comes at a high price and the aforementioned risks of stent placement. Use of more than one DCB per intervention significantly decreases their cost-effectiveness. At 2 years, DCBs emerge more clearly as the most cost-effective index strategy with the lowest overall cost and highest patency rates over that time horizon. 
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